ISB News

Ranish Lab Receives $156K Grant

Jeff Ranish

Jeff Ranish is an assistant professor at ISB. His expertise includes proteomics, macromolecular complexes and transcriptional regulation.

Congratulations to ISB faculty member Jeff Ranish and his group on receiving a new grant for $156,000. The award is for collaborative work with Peter Myler at Seattle BioMed on “Base J and transcription termination in Leishmania.”

Here’s the public health relevance statement from the proposal:

Human infections with the various species of Leishmania parasite cause substantial morbidity and mortality in tropical and sub-tropical countries world-wide. These organisms appear to differ from their animal hosts in the way that they transcribe the genetic information in their genomic DNA into messenger RNAs, which are used to make the proteins. These studies are designed to elucidate parasite-specific differences in this vital process, which we hope may be exploited for the development of novel anti-Leishmania drugs.

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.